
|Videos|May 20, 2022
Results of phase 3 PADRES trial of neoadjuvant axitinib in renal cell carcinoma
Author(s)Urology Times staff
Advertisement
Lead author Kevin Hakimi discusses the background and results of the study, “Interim analysis of
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Ac-225 rosopatamab tetraxetan shows promising activity in Lu-PSMA–pretreated mCRPC
2
5 urologic oncology headlines you missed in Q2 2026
3
5 benign urology headlines you missed in Q2 2026
4
Helen L. Bernie, DO, MPH, on counseling patients through TRT and prostate cancer uncertainty
5













